- Corcept Therapeutics ( NASDAQ: CORT ) on Tuesday said it had started a phase 2 trial of its modulator dazucorilant for the treatment of neurodegenerative disease amyotrophic lateral sclerosis (ALS).
- The mid-stage study, called DAZALS, is expected to enroll 198 ALS patients.
- "Dazucorilant showed great promise in animal models of ALS – improving motor performance and reducing neuroinflammation and muscular atrophy," the trial's principal investigator said in a statement .
- The main goals of the study will be ALS Functional Rating Scale-Revised total score and safety, CORT said.
- The ALS space recently saw the approval of Amylyx Pharmaceuticals' ( AMLX ) Relyvrio by the U.S. FDA in late Sept., despite concerns over the effectiveness of the drug.
- Corcept Therapeutics ( CORT ) stock earlier closed +1.8% at $26.53.
For further details see:
Corcept Therapeutics starts phase 2 trial of its ALS treatment